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Abstract: Pseudomonas aeruginosa is a common pathogen implicated in nosocomial 
infections with increasing resistance to a limited arsenal of antibiotics. Monte Carlo 
simulation provides antimicrobial stewardship teams with an additional tool to guide empiric 
therapy. We modeled empiric therapies with antipseudomonal β-lactam antibiotic regimens 
to determine which were most likely to achieve probability of target attainment (PTA)  
of >90%. Microbiological data for P. aeruginosa was reviewed for 2012. Antibiotics  
modeled for intermittent and prolonged infusion were aztreonam, cefepime, meropenem,  
and piperacillin/tazobactam. Using minimum inhibitory concentrations (MICs) from  
institution-specific isolates, and pharmacokinetic and pharmacodynamic parameters from 
previously published studies, a 10,000-subject Monte Carlo simulation was performed for 
each regimen to determine PTA. MICs from 272 isolates were included in this analysis. No 
intermittent infusion regimens achieved PTA >90%. Prolonged infusions of cefepime 2000 mg 
Q8 h, meropenem 1000 mg Q8 h, and meropenem 2000 mg Q8 h demonstrated PTA of 93%, 
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92%, and 100%, respectively. Prolonged infusions of piperacillin/tazobactam 4.5 g Q6 h and 
aztreonam 2 g Q8 h failed to achieved PTA >90% but demonstrated PTA of 81% and 73%, 
respectively. Standard doses of β-lactam antibiotics as intermittent infusion did not achieve 
90% PTA against P. aeruginosa isolated at our institution; however, some prolonged 
infusions were able to achieve these targets. 
Keywords: antimicrobial stewardship; pharmacodynamics; Pseudomonas aeruginosa; 
pharmacokinetics; modeling 
 
1. Introduction 
Pseudomonas aeruginosa is a ubiquitous Gram negative organism that has been implicated as  
the causative pathogen in many nosocomial infections. According to the National Healthcare Safety 
Network, P. aeruginosa is the fifth most common cause of hospital-acquired infections [1]. Mortality 
due to P. aeruginosa infection is high with some studies estimating mortality rate around 40% [2,3]. 
Antimicrobial stewardship programs (ASPs) must provide guidance to clinicians to help influence 
therapy selection and antimicrobial utilization. Successfully doing so will optimize both patient 
outcomes and healthcare costs, and curtail the development of antimicrobial resistance [4]. Infections 
due to P. aeruginosa are particularly challenging as designing effective antimicrobial regimens is 
hampered by growing resistance to a limited number of active agents. Consequences of ineffective 
antimicrobial therapy are increased mortality and costs of care [1,5–7]. One tool that ASPs can use to 
guide antipseudomonal therapy is the institutional antibiogram: the collection of quantitative minimum 
inhibitory concentrations (MIC) and reporting of qualitative susceptibility results for the microbial 
isolates at a given institution [8]. However, antibiograms only provide the likelihood that a  
pathogen will be susceptible to a given antimicrobial agent as defined by regulatory bodies based on 
historical data. The selected agent must be administered at appropriate doses to optimize antimicrobial 
pharmacokinetic and pharmacodynamic parameters [9]. 
Monte Carlo simulations can be used by ASPs as an extension of the antibiogram to guide optimal 
dosing of antimicrobials. A Monte Carlo simulation is a mathematical model developed in the 1940s to 
simulate scenarios that require the generation of random numbers. It has many applications in physics, 
finance and business, artificial intelligence, and video game design. In the setting of antimicrobial 
therapeutics, Monte Carlo simulations can combine pharmacokinetic and microbiological data to predict 
the likelihood an antimicrobial regimen will achieve a therapeutic target [10]. This is called the 
probability of target attainment (PTA) where the target to be achieved is an optimal pharmacodynamic 
parameter for bacterial killing [11]. This study aims to determine which empiric beta-lactam antimicrobial 
regimens will achieve a PTA of at least 90% against P. aeruginosa isolates at our institution. 
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2. Methods 
2.1. Data Collection 
This was a single-center, retrospective analysis conducted at University of Kentucky Chandler 
Medical Center, a 718-bed academic medical center. This study was approved by the Institutional 
Review Board. Clinical microbiology laboratory data was obtained for P. aeruginosa isolates collected 
between 1 January 2012 and 31 December 2012. Samples included for analysis were isolated from 
patients >18 years old who were admitted as inpatients during the study period. The first positive isolate 
from any culture site per year for P. aeruginosa from each patient was included for analysis. Subsequent 
positive cultures were excluded as recommended by antibiogram guidelines [8]. Culture sources 
included blood, bone, intra-abdominal, respiratory, skin/wound, urine, and miscellaneous sites.  
Data collected included source of isolate, patient location within hospital, and minimum inhibitory 
concentration (MIC) for formulary anti-pseudomonal beta-lactam antibiotics. At the time of study, MICs 
were reported using the BD Phoenix® automated microbiology system. The anti-pseudomonal beta-lactam 
antibiotics on formulary include aztreonam, cefepime, meropenem, and piperacillin/tazobactam. 
A PubMed search of the primary literature was conducted a priori to identify pharmacokinetic 
parameters for incorporation into the pharmacodynamic model. Search terms included the name of the 
agent, “healthy”, “volunteer”, and “pharmacokinetics”. Pharmacokinetic parameters collected from the 
identified studies included total body clearance (ClTB), volume of distribution (Vd), and half-life (t1/2). 
Protein binding (PB) was obtained from the manufacturers’ package inserts. 
2.2. Model Construction 
A 10,000 trial Monte Carlo simulation was constructed for each antimicrobial regimen in Oracle® 
Crystal Ball for Microsoft Excel® (version 11.1.2, Redwood City, CA, USA). Commonly prescribed 
doses were analyzed as both intermittent infusion (30 min) and prolonged infusion (3 h) for each 
antibiotic. The pharmacodynamic target used was free time above MIC (f%T > MIC). The optimal f%T 
> MIC used for carbapenems was 40% of the dosing interval, for cephalosporins and aztreonam was 
70%, and for penicillins was 50%. These values have correlated with bacterial killing, and reduced 
mortality in vivo [9]. 
Intermittent infusion [12]: %T	 > MIC = ln dose	 ×	(1 − PB) ÷ (V × MIC) × (V ÷ Cl ) × (100 ÷ τ) (1)
Prolonged infusion [13]: %T > MIC = T −	 ln (R ÷ Cl ) ÷ (R ÷ Cl − MIC) × (t / ÷ 0.693)+	 ln(R ÷ Cl ) − ln(MIC) × (t / ÷ 0.693) × (100τ ) (2)R = dose	 ×	(1 − PB) /T , Tinf = infusion time, τ = dosing interval (3)
The model identifies a pharmacokinetic parameter that falls within a lognormal distribution of the 
standard deviation about the mean and incorporates that into each simulation. Each simulation incorporated 
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an MIC from the distribution of MICs identified from microbiologic data in order to mimic practice where 
clinicians do not know the MIC of the organism upon initiation of empiric antimicrobial therapy. 
3. Results 
Two hundred seventy-two P. aeruginosa isolates were identified for inclusion. Sixty-one percent of 
isolates were from male patients and 39% were from females. Forty-seven percent of specimens were 
isolated from patients admitted to a surgical or medical intensive care unit, 40% were isolated from 
patients admitted to an acute care service, 8% were admitted to our institution’s oncology wing, and 
location was unknown in 4% of cases. The most common sources were respiratory (42%), skin/wound 
(24%), urine (19%), blood (8%), and miscellaneous sites (5%). 
Table 1 indicates the distribution of MICs reported for study antibiotics and the percent of susceptible 
isolates according to 2012 Clinical and Laboratory Standards Institute (CLSI) standards [14]. The MIC50, 
and MIC90 of P. aeruginosa isolates are also presented in Table 1. Cefepime (81%) had the highest 
susceptibility rate against P. aeruginosa. 
Table 1. (Minimum inhibitory concentrations) MIC Range, MIC50, and MIC90, and percent 
susceptible against P. aeruginosa isolates from University of Kentucky. 
 
Breakpoint a 
(mcg/mL) 
MIC Range 
(mcg/mL) 
MIC50 
(mcg/mL) 
MIC90 
(mcg/mL) 
% 
Susceptible 
Aztreonam 8 <2–>32 8 32 68 
Cefepime 8 <1–>32 4 16 81 
Meropenem 2 <1–>16 1 8 74 
Piperacillin 16 <2–>128 8 128 75 
MIC = minimum inhibitory concentration, mcg/mL; MIC50 = MIC value at which growth was inhibited in 50% 
of isolates; MIC90 = MIC values at which growth was inhibited in 90% of isolates; a According to 2012 CLSI 
guidelines [14]. 
Identified pharmacokinetic studies and parameters included in the Monte Carlo simulation model are 
listed in Table 2. Data is presented as mean values and standard deviation. In one study of meropenem 
pharmacokinetics, no standard deviation was provided for t1/2, so a variation of 10% was set in  
the model [15]. Figure 1 presents the PTA for empiric antimicrobial regimens across the range of  
MICs encountered at our institution. Intermittent infusions of beta-lactams over 30 min did not reach 
pharmacodynamic targets in 90% of simulations. Prolonged infusions of cefepime 2000 mg every 8 h, 
meropenem 1000 mg every 8 h, and meropenem 2000 mg every 8 h have 93%, 92%, and 100% probability 
of reaching pharmacodynamic targets, respectively. 
Table 2. Pharmacokinetic parameters incorporated into model. 
Antimicrobial Agent 
Clearance 
(L/h) 
Volume of 
Distribution (L) 
Half Life 
(h) 
Protein 
Binding (%) 
Aztreonam [16,17] 5.45 ± 1.24 13.7 ± 4.94 1.69 ± 0.43 56 
Cefepime [18,19] 8.58 ± 1.5 18.4 ± 3.8 2.32 ± 0.39 20 
Meropenem [15,20] 11.28 ± 1.86 12.5 ± 1.5 0.98 2 
Piperacillin [21,22] 11.07 ± 2.59 11.2 ± 2.1 0.7 ± 0.11 30 
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Figure 1. Probability of target attainment of optimized empiric antipseudomonal beta-lactams. 
ATM = aztreonam; CFP = cefepime; MER = meropenem; PTZ = piperacillin/tazobactam. 
4. Discussion 
Pseudomonas aeruginosa is a major pathogen implicated in nosocomial infections. Successful 
treatment of P. aeruginosa is difficult due to limited antimicrobial options and increasing drug 
resistance. Providing guidance for the treatment of P. aeruginosa is particularly challenging for 
antimicrobial stewardship practitioners who must balance using effective antimicrobials, preserving the 
utility of these agents and managing healthcare costs. Antipseudomonal treatment success is not only 
dependent on appropriate antimicrobial agent choice but also on optimal dosing to achieve 
pharmacodynamic targets. We used institutional MIC data and healthy volunteer pharmacokinetic  
data to model pharmacodynamic target attainment of available empiric β-lactam regimens used when  
P. aeruginosa is suspected. 
Results of this study show that intermittent infusions of meropenem and prolonged infusions of 
meropenem or cefepime are most likely to achieve PTA >90% against P. aeruginosa isolates at our 
institution. Interestingly, prolonged infusion regimens of piperacillin/tazobactam were not able to reach 
PTA >90%, even at high doses of 4000 mg every 6 h. This may be attributable to high MICs of 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
ATM 2g Q8 h CFP 2g Q8 h MER 1g Q8 h MER 2g Q8 h PTZ 3.375g
Q6 h
PTZ 4.5g Q6 h
Intermittent Infusion (30 mins) Prolonged Infusion (3 hrs)
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piperacillin/tazobactam against P. aeruginosa in our population. In the range of MICs encountered 
against P. aeruginosa in this study, the highest MICs were for piperacillin/tazobactam. Eight percent of 
isolates had an MIC of 64 mcg/mL and 10% had an MIC of 128 mcg/mL. The tested antimicrobial 
regimens are more likely to reach PTA against isolates expressing lower MICs and less likely to reach 
these targets when the MIC is at the higher end of the range. Additionally, in patients with normal renal 
function—as modeled in this study—it is unfeasible to reach and maintain therapeutic serum 
concentrations above the MIC for 50% of the dosing interval when the MICs are elevated. 
The current study is not the only example of using institution-specific isolates in Monte Carlo 
simulations to influence antimicrobial dosing practices. Goff et al. analyzed 64 P. aeruginosa isolates 
from their institution and conducted a Monte Carlo Simulation to determine PTA for carbapenems  
and cefepime. Cefepime 2000 mg every 8 h administered over 0.5–1 h achieved a PTA of 86% while 
infusion over 3–4 h achieved a PTA greater than 90%. The antimicrobial stewardship team at their 
institution decided to change empiric cefepime dosing to prolonged infusion with resultant reductions in 
length of stay in both the hospital and the ICU, 14-day mortality, and in-hospital mortality [23]. 
Another study evaluated implementation of a clinical pathway for antimicrobial therapy in  
ventilator-associated pneumonia (VAP). A clinical pathway was designed using Monte Carlo simulation 
results from MICs against P. aeruginosa isolated from respiratory sources in three intensive care units 
between November 2004 and July 2005. Based on Monte Carlo simulations, cefepime 2000 mg prolonged 
infusion every 8 h, meropenem 2000 mg prolonged infusion every 8 h, and piperacillin/tazobactam  
4.5 g prolonged infusion every 6 h or 18 g continuous infusion every 24 h had the highest PTA against 
P. aeruginosa in the population of ICU patients with VAP. After implementing this clinical pathway, 
patients had decreased infection-related mortality, improved time to appropriate antimicrobial therapy, 
and decreased infection-related length of stay [24]. 
This study is limited in that it is a retrospective review of microbiological data and makes predictions 
based on mathematical modeling. While it reflects current guidelines regarding construction of an 
institutional antibiogram by including data from one institution, other institutions may have differing 
results [25]. Antimicrobial stewards must consider their institutional microbiome and local susceptibility 
patterns when making empiric therapy decisions. Future application includes using the Monte Carlo 
methodology with unit-specific isolates as CLSI encourages stratification of cumulative antibiogram 
data by nursing unit or site of care [25]. 
Our model was based on population pharmacokinetics from normal weight, healthy volunteers.  
In our patient population, 47% were located in an intensive care unit, creating the potential for 
confounding. We chose healthy volunteer population due to homogeneity and consistency of data 
throughout the published pharmacokinetic literature. In a study by Lodise et al. that conducted Monte 
Carlo simulations using pharmacokinetic parameters simulated from hospitalized patients and collected 
from healthy subject studies, the healthy subject studies underestimated PTA [26]. Therefore, the results 
of our study likely reflect worst-case, lower PTA than what would be achieved clinically. These results 
should be applied cautiously for patients with alterations in clearance or volume of distribution. 
Additionally, our model is built around predicted serum concentrations of the tested antimicrobials. 
Future models for specific sites of infection should incorporate tissue penetration to calculate PTA. 
The PTA goals in our model were conservative and represent optimal pharmacodynamic outcomes 
to maximize bacterial killing in vitro, but there is a paucity in the current body of literature to support 
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clinical outcomes associated with targeting these optimal pharmacodynamic targets using Monte Carlo 
simulation, and available published studies are conflicting [9]. One study conducted by Fish et al. 
compared outcomes predicted by Monte Carlo simulation with actual clinical outcomes in 182 critically 
ill patients with P. aeruginosa pneumonia [27]. Both modeling and direct estimation were used to 
ascertain pharmacodynamic targets. There was no correlation between actual clinical response to therapy 
and Monte Carlo simulation predicted target attainment. 
These studies and the current study set the stage for future direction of the application of Monte Carlo 
simulation in ASPs. They can be used as an extension of the antibiogram, inform institutional clinical 
pathway design, and influence physicians to choose the correct agent, dose, route, and dosing interval. 
These are important metrics of antimicrobial use processes that can be evaluated by ASPs  
to track and optimize antimicrobial utilization [28]. Since the execution of the current study, the 
antimicrobial management team provides practitioners at our institution with Monte Carlo simulation 
data in addition to the annual antibiogram to help guide empiric therapy for both P. aeruginosa and 
Enterobacteriaceae. Future applications include building Monte Carlo models to evaluate the dosing 
regimens of new antipseudomonal agents. Ceftolozane-tazobactam and ceftazidime-avibactam were 
recently approved for the treatment of complicated intra-abdominal infection or complicated urinary 
tract infection [29–32]. Monte Carlo simulations utilizing pharmacokinetics of these agents in patients 
combined with local isolates can provide direction for clinicians on use in more difficult to treat 
infections such as pneumonia and bacteremia. Additionally, currently utilized dosing schemes can be 
evaluated against clinical isolates as these agents begin to be used in practice. Around 3% of tested  
P. aeruginosa demonstrated resistant MICs with these new agents which may require higher doses, 
shorter intervals, and/or prolonged infusions to achieve pharmacodynamic targets and bactericidal 
activity [33,34]. Antimicrobial stewardship teams must ensure that these new agents are utilized 
appropriately and dosed optimally to preserve activity against P. aeruginosa. 
5. Conclusions 
ASPs can use Monte Carlo simulations as another tool in addition to the antibiogram to determine 
optimal empiric therapy regimens. Using local microbiology data and pharmacokinetic data, ASPs  
can develop unit-specific or institution-wide empiric regimens to target P. aeruginosa. Manipulating 
dosing and administration modalities can achieve optimal pharmacodynamic targets to improve the 
likelihood of successfully treating an infection. At our institution, prolonged infusions of high  
dose cefepime and meropenem achieved pharmacodynamics targets against P. aeruginosa. There are 
opportunities for further studies to examine the clinical application of Monte Carlo simulations in 
designing empiric antimicrobial therapy. 
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